Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.
The University of California, San Francisco and Thermo Fisher Scientific have opened a new cGMP manufacturing facility specialising in advanced cell therapies for the treatment of cancer, rare diseases, and other difficult-to-treat illnesses. The facility sits adjacent to the UCSF Medical Center’s Mission Bay campus.
First announced in 2021, the partnership between Thermo Fisher and UCSF will enable scientists, clinicians, and patients closer access to a manufacturing site, and potentially demonstrate how the development of breakthrough treatments may be expedited with increased access to state-of-the-art facilities. The initial focus of the site will be the development of treatments for glioblastomas, multiple myeloma, and other forms of cancer utilising updated approaches on CAR T and CRISPR technologies.
Executive VP and COO of Thermo Fisher Michel Lagarde stated: “Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications. With a record number of cell therapy approvals granted in the last 2 years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology where new technologies and partnerships are evolving and transforming clinical care.”
As part of Thermo Fisher’s global network of pharmaceutical and therapeutic services, including over 15 locations servicing cell and gene therapies, the facility will offer the UCSF community and other customers process and analytical capabilities, and clinical and commercial manufacturing services for advanced cell and gene therapies. Drug development, discovery, and commercialisation will also be accessible for those looking to benefit from Thermo Fisher’s therapeutic development capabilities with this San Francisco facility.

UCSF Chancellor, Sam Hawgood, commented on the site establishment: “UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next generation of CAR-T therapy development. These approaches will be tested soon in patients with solid tumours like glioblastoma and later in other diseases, including autoimmunity.”
Source: Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies [Accessed March 27 2023] https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx
Stay up to date with the latest developments at CPHI Barcelona
Across the industry, businesses large and small are making huge strides forward. At CPHI Barcelona, you can hear from – and meet – representatives from all kinds of pharma enterprises. Find out how they're driving themselves forward and be inspired.
Your CPHI Barcelona pass gives you access to all conference sessions, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...